Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
暂无分享,去创建一个
Joon-Oh Park | M. Buyse | Y. Bang | Jianming Xu | J. Hecht | Z. Wainberg | D. Slamon | M. Press | P. Hoff | Jin Li | V. Houé | H. Chung | P. Salman | S. Qin | A. Sobrero | Y. Shparyk | S. Protsenko | K. Jeziorski | K. Afenjar | Tomomi Kaneko | S. Santillana | Yingjie Huang | T. Kaneko | S. Khan-Wasti | Agathe Garcia
[1] N. Syn,et al. Chemotherapy for advanced gastric cancer. , 2017, The Cochrane database of systematic reviews.
[2] N. Zhong,et al. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial , 2015, Current medical research and opinion.
[3] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[4] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[5] Y. Bang,et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Riley,et al. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081 , 2013, European Respiratory Journal.
[7] T. Whelan,et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Khay Guan Yeoh,et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets , 2012, Gut.
[9] E. Chiorean. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study , 2012 .
[10] Chia Huey Ooi,et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. , 2011, Gastroenterology.
[11] H. Lenz,et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[13] Zev A Wainberg,et al. Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo , 2010, Clinical Cancer Research.
[14] D. Cunningham,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2010, The New England journal of medicine.
[15] A. Stead,et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Arbushites,et al. HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer , 2008, Clinical Cancer Research.
[17] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[18] J. Ajani,et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Ajani,et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group , 2006 .
[20] W. MacNee,et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.
[21] E. Cook,et al. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .
[23] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[24] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[25] H. Allgayer,et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.